| scholarly article | Q13442814 |
| P2093 | author name string | Milind Javle | |
| Jeffrey Lombardo | |||
| Amitkumar Pande | |||
| Edward Spangenthal | |||
| P433 | issue | 5B | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| angiogenesis inhibitor | Q574834 | ||
| hypertension | Q95566669 | ||
| P304 | page(s) | 3465-3470 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Anticancer Research | Q326290 |
| P1476 | title | Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab | |
| P478 | volume | 27 |
| Q49188770 | Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review |
| Q24657761 | Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment |
| Q34152125 | Anti-VEGF Cancer Therapy in Nephrology Practice |
| Q38757141 | Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options |
| Q33401202 | Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. |
| Q35703835 | Cancer therapy and cardiovascular risk: focus on bevacizumab |
| Q39474625 | Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. |
| Q45397146 | Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization |
| Q33807542 | Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives |
| Q38819670 | Cardiotoxicity associated with targeted cancer therapies |
| Q37788952 | Cardiotoxicity of anticancer treatments: what the cardiologist needs to know |
| Q34258080 | Chemotherapy-induced cardiotoxicity |
| Q37355708 | Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. |
| Q45917757 | First annual Canadian Cardiac Oncology Network conference. |
| Q37725536 | IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients |
| Q42366660 | Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment |
| Q89357784 | Management of VEGF-Targeted Therapy-Induced Hypertension |
| Q36170252 | Management of antiangiogenic therapy-induced hypertension |
| Q33572306 | Molecular regulation of tumor angiogenesis and perfusion via redox signaling |
| Q37498854 | Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? |
| Q91679389 | Pharmacogenetic Implications of eNOS Polymorphisms (Glu298Asp, T786C, 4b/4a) in Cardiovascular Drug Therapy |
| Q37385797 | Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies |
| Q38448007 | Renal Toxicities of Targeted Therapies |
| Q55360813 | Research progress on common adverse events caused by targeted therapy for colorectal cancer. |
| Q99630612 | Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series |
| Q50967704 | Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration. |
| Q36526512 | The VEGF pathway in cancer and disease: responses, resistance, and the path forward. |
| Q36630478 | The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. |
| Q53167121 | Treatment of bevacizumab-induced hypertension by amlodipine. |
Search more.